IRIS Accounts Production v26.1.10.61 SC213462 Board of Directors 1.1.25 31.12.25 31.12.25 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhSC2134622024-12-31SC2134622025-12-31SC2134622025-01-012025-12-31SC2134622023-12-31SC2134622024-01-012024-12-31SC2134622024-12-31SC213462ns15:Scotland2025-01-012025-12-31SC213462ns14:PoundSterling2025-01-012025-12-31SC213462ns10:Director12025-01-012025-12-31SC213462ns10:PrivateLimitedCompanyLtd2025-01-012025-12-31SC213462ns10:SmallEntities2025-01-012025-12-31SC213462ns10:AuditExempt-NoAccountantsReport2025-01-012025-12-31SC213462ns10:SmallCompaniesRegimeForDirectorsReport2025-01-012025-12-31SC213462ns10:SmallCompaniesRegimeForAccounts2025-01-012025-12-31SC213462ns10:FullAccounts2025-01-012025-12-31SC21346212025-01-012025-12-31SC213462ns10:Director22025-01-012025-12-31SC213462ns10:Director32025-01-012025-12-31SC213462ns10:Director42025-01-012025-12-31SC213462ns10:Director52025-01-012025-12-31SC213462ns10:RegisteredOffice2025-01-012025-12-31SC213462ns5:CurrentFinancialInstruments2025-12-31SC213462ns5:CurrentFinancialInstruments2024-12-31SC213462ns5:Non-currentFinancialInstruments2025-12-31SC213462ns5:Non-currentFinancialInstruments2024-12-31SC213462ns5:ShareCapital2025-12-31SC213462ns5:ShareCapital2024-12-31SC213462ns5:SharePremium2025-12-31SC213462ns5:SharePremium2024-12-31SC213462ns5:RetainedEarningsAccumulatedLosses2025-12-31SC213462ns5:RetainedEarningsAccumulatedLosses2024-12-31SC213462ns5:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-31SC213462ns5:PlantMachinery2025-01-012025-12-31SC213462ns5:PatentsTrademarksLicencesConcessionsSimilar2024-12-31SC213462ns5:PatentsTrademarksLicencesConcessionsSimilar2025-12-31SC213462ns5:PatentsTrademarksLicencesConcessionsSimilar2024-12-31SC213462ns5:PlantMachinery2024-12-31SC213462ns5:ComputerEquipment2024-12-31SC213462ns5:ComputerEquipment2025-01-012025-12-31SC213462ns5:PlantMachinery2025-12-31SC213462ns5:ComputerEquipment2025-12-31SC213462ns5:PlantMachinery2024-12-31SC213462ns5:ComputerEquipment2024-12-31SC213462ns5:WithinOneYearns5:CurrentFinancialInstruments2025-12-31SC213462ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-31SC213462ns5:CurrentFinancialInstruments2025-01-012025-12-31SC21346212025-01-012025-12-31
REGISTERED NUMBER: SC213462 (Scotland)












NANDI PROTEINS LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025






NANDI PROTEINS LIMITED (REGISTERED NUMBER: SC213462)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


NANDI PROTEINS LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2025







DIRECTORS: Dr L J Campbell
Mr H J P Stewart
Mr J R Price
Mr M C White
Mr D C Flower





REGISTERED OFFICE: 5 South Charlotte Street
Edinburgh
EH2 4AN





REGISTERED NUMBER: SC213462 (Scotland)





ACCOUNTANTS: Rushtons
Chartered Accountants
Shorrock House
1 Faraday Court
Fulwood
Preston
Lancashire
PR2 9NB

NANDI PROTEINS LIMITED (REGISTERED NUMBER: SC213462)

BALANCE SHEET
31 DECEMBER 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 - 2,496
- 2,496

CURRENT ASSETS
Debtors 6 46,774 31,962
Cash at bank 20,687 17,560
67,461 49,522
CREDITORS
Amounts falling due within one year 7 290,809 68,182
NET CURRENT LIABILITIES (223,348 ) (18,660 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(223,348

)

(16,164

)

CREDITORS
Amounts falling due after more than
one year

8

(2,046,690

)

(3,068,685

)

PROVISIONS FOR LIABILITIES - (278 )
NET LIABILITIES (2,270,038 ) (3,085,127 )

NANDI PROTEINS LIMITED (REGISTERED NUMBER: SC213462)

BALANCE SHEET - continued
31 DECEMBER 2025

2025 2024
Notes £    £    £    £   
CAPITAL AND RESERVES
Called up share capital 2,394 2,042
Share premium 4,858,053 3,626,312
Retained earnings (7,130,485 ) (6,713,481 )
SHAREHOLDERS' FUNDS (2,270,038 ) (3,085,127 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Comprehensive Income has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 20 July 2026 and were signed on its behalf by:





Mr J R Price - Director


NANDI PROTEINS LIMITED (REGISTERED NUMBER: SC213462)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1. STATUTORY INFORMATION

Nandi Proteins Limited is a private company, limited by shares , registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Grant income is recognised on receipt of the income.

A technology licensed fee is recognised as at the date of the sales invoice.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents are being amortised evenly over their estimated useful life of 2 and 5 years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 20% on cost

Tangible assets are initially recognised at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


NANDI PROTEINS LIMITED (REGISTERED NUMBER: SC213462)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2025

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research costs is written off in the year in which it is incurred.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Going concern
The directors have decided to change the business in 2026 to a low cost, licensing model. All staff have been removed, facilities shut down and the entity is to collect royalties in order to meet its obligations.To assist with this funds have been raised since the year end through an unsecured loan note instrument. In addition, and at the same time, the Company entered into an inter creditor agreement with creditors which provides for settlement from cash in excess of working capital requirements. The Directors are therefore confident that the company will have sufficient funds to enable it to trade for more than twelve months beyond the date of signing the accounts.

The company will also be taking advantage of any and all grants available.

As such, the company continues to adopt the going concern basis in preparing the financial statements.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 5 (2024 - 5 ) .

NANDI PROTEINS LIMITED (REGISTERED NUMBER: SC213462)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2025

4. INTANGIBLE FIXED ASSETS
Patents
and
licences
£   
COST
At 1 January 2025
and 31 December 2025 10,178
AMORTISATION
At 1 January 2025
and 31 December 2025 10,178
NET BOOK VALUE
At 31 December 2025 -
At 31 December 2024 -

5. TANGIBLE FIXED ASSETS
Plant and Computer
machinery equipment Totals
£    £    £   
COST
At 1 January 2025 4,919 2,775 7,694
Disposals (4,919 ) (2,775 ) (7,694 )
At 31 December 2025 - - -
DEPRECIATION
At 1 January 2025 3,255 1,943 5,198
Charge for year 935 423 1,358
Eliminated on disposal (4,190 ) (2,366 ) (6,556 )
At 31 December 2025 - - -
NET BOOK VALUE
At 31 December 2025 - - -
At 31 December 2024 1,664 832 2,496

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Tax 35,235 15,824
VAT 1,971 6,444
Prepayments 9,568 9,694
46,774 31,962

NANDI PROTEINS LIMITED (REGISTERED NUMBER: SC213462)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2025

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade creditors 26,222 2,249
Social security and other taxes 7,833 51,152
Other creditors 176,904 3,320
Accrued expenses 79,850 11,461
290,809 68,182

Included within other creditors is £174k relating to advance subscription agreements which were converted into shares in February 2026 as described in note 10.

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN
ONE YEAR
2025 2024
£    £   
Trade creditors 458,855 374,855
Other creditors 568,151 817,820
Other loans 1,019,684 1,876,010
2,046,690 3,068,685

9. RELATED PARTY DISCLOSURES

The following transactions occurred during the year with related parties:

2025 2024
£ £

Management charges from the shareholder Frontier 48,000 50,500
IP Limited
Management charges from Shackleton Ventures 12,000 12,000
Limited, in which Mr H Stewart is a Director
Amounts owed to Frontier IP Limited in trade 378,455 320,855
creditors
Amounts owed to Shackleton Ventures Limited in 68,400 54,000
trade creditors
Amounts owed to Shareholders in other creditors 431,820 53,250
Amounts owed to Companies with a common Director in 94,370 -
other creditors
Amounts owed to Directors in other creditors 4,235 -
Management charges from Mr J R Price - 24,000
Loan notes due to Shareholders/related parties 616,000 1,116,000
Loan notes due to Companies with a common 100,000 140,000
Director
Loan notes due to Directors 53,684 10,000
ASA due to Shareholders/related parties 33,700 33,700
ASA due to Companies with a common Director 140,300 140,300

NANDI PROTEINS LIMITED (REGISTERED NUMBER: SC213462)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2025

10. POST BALANCE SHEET EVENTS

On 15 February 2026 the Company issued 5,409 A ordinary shares of £0.01 each on the conversion of advance subscription agreements of £174,000.

On 17 February 2026 the Company issued loan notes of £130,000.

On 17 February 2026 the Company entered into an Intercreditor Agreement relating to the priority of unsecured creditors with Nesta Partners Limited, Scottish Enterprise, Frontier IP Limited, Shackleton Secondaries 3 LP, Shackleton Ventures Limited, Shackleton Finance Limited, Price Hambleton Investments Limited, David Flower and Lydia Campbell totalling £2,141,689 at 31 December 2025.

On 15 April 2026 the Company purchased and cancelled 14,018 A ordinary shares of £0.01 each for consideration of £14.08.

On 27 April 2026 Lydia Campbell resigned as a director.

11. ULTIMATE CONTROLLING PARTY

In the opinion of the directors there is no overall controlling party at the balance sheet date.

12. RIGHTS OF SHARES

Return of capital

Subject to the articles of association, on a winding up, share capital reduction or other return or distribution of capital or assets, any capital or assets shall be returned or distributed to the holders of Equity Shares (irrespective of class) pro rata according to the numbers of shares (irrespective of class) held by them respectively.

Voting rights

All classes of shares carry equal voting rights.

Options have been granted to subscribe for shares of the company as follows:



Date of
issue
Number
of shares
at
01.01.25
Number
of
shares
issued
Number
of shares
at
31.12.25


Exercise
price



Share type


Expiry
date
24.01.22 10,132 10,132 £17.30 1p A Ordinary 24.01.32
31.01.22 5,984 5,984 £17.30 1p A Ordinary 31.01.32